Albemarle (NYSE:ALB – Get Free Report) had its price objective decreased by stock analysts at Scotiabank from $160.00 to $150.00 in a research note issued on Monday, Benzinga reports. The firm presently has a “sector outperform” rating on the specialty chemicals company’s stock. Scotiabank’s target price would indicate a potential upside of 13.96% from the company’s previous close. Scotiabank also issued estimates for Albemarle’s FY2024 earnings at $2.39 EPS.
ALB has been the topic of several other reports. KeyCorp reduced their target price on Albemarle from $178.00 to $159.00 and set an “overweight” rating on the stock in a report on Thursday, March 7th. TD Cowen lowered Albemarle from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $220.00 to $130.00 in a report on Monday, January 29th. Mizuho increased their target price on Albemarle from $112.00 to $128.00 and gave the stock a “neutral” rating in a report on Thursday, May 2nd. Wells Fargo & Company increased their target price on Albemarle from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Finally, Royal Bank of Canada raised their price objective on Albemarle from $138.00 to $157.00 and gave the company an “outperform” rating in a research note on Monday. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Albemarle has a consensus rating of “Hold” and an average target price of $172.05.
Check Out Our Latest Stock Analysis on ALB
Albemarle Stock Performance
Albemarle (NYSE:ALB – Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The specialty chemicals company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.09). Albemarle had a net margin of 4.02% and a return on equity of 14.53%. The firm had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the prior year, the company earned $10.32 earnings per share. The business’s quarterly revenue was down 47.3% compared to the same quarter last year. On average, equities analysts forecast that Albemarle will post 2.86 EPS for the current year.
Hedge Funds Weigh In On Albemarle
A number of hedge funds have recently made changes to their positions in ALB. Assetmark Inc. acquired a new stake in Albemarle during the third quarter worth approximately $25,000. WFA Asset Management Corp acquired a new stake in Albemarle during the first quarter worth approximately $25,000. USCF Advisers LLC grew its stake in Albemarle by 100.0% during the fourth quarter. USCF Advisers LLC now owns 200 shares of the specialty chemicals company’s stock worth $29,000 after purchasing an additional 100 shares during the period. Arlington Trust Co LLC acquired a new stake in Albemarle during the fourth quarter worth approximately $30,000. Finally, Jones Financial Companies Lllp grew its stake in Albemarle by 2,942.9% during the fourth quarter. Jones Financial Companies Lllp now owns 213 shares of the specialty chemicals company’s stock worth $31,000 after purchasing an additional 206 shares during the period. 92.87% of the stock is currently owned by institutional investors.
About Albemarle
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.
Read More
- Five stocks we like better than Albemarle
- What is the Dogs of the Dow Strategy? Overview and Examples
- Garmin Navigates to New Highs Driven By Wearables Trend
- P/E Ratio Calculation: How to Assess Stocks
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.